Oxford Biomedica Plc

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BDFBVT43
GBP
6.17
-4.33 (-41.24%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor Management Efficiency with a low ROE of 2.05%

  • The company has been able to generate a Return on Equity (avg) of 2.05% signifying low profitability per unit of shareholders funds
2

Poor long term growth as Operating profit has grown by an annual rate -186.74% of over the last 5 years

 
3

Flat results in Jun 25

4

Risky -

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 747 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.38

stock-summary
Return on Equity

-119.43%

stock-summary
Price to Book

22.82

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-43.55%
0%
-43.55%
6 Months
-30.67%
0%
-30.67%
1 Year
-12.48%
0%
-12.48%
2 Years
-28.75%
0%
-28.75%
3 Years
4646.15%
0%
4646.15%
4 Years
10183.33%
0%
10183.33%
5 Years
6260.82%
0%
6260.82%

Oxford Biomedica Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
18.06%
EBIT Growth (5y)
-186.74%
EBIT to Interest (avg)
-0.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
0.90
Tax Ratio
2.84%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.07%
ROE (avg)
2.05%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
23.54
EV to EBIT
-22.54
EV to EBITDA
-82.76
EV to Capital Employed
37.36
EV to Sales
5.01
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-165.76%
ROE (Latest)
-119.43%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Oxford Biomedica Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 43.91% vs -36.07% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 73.62% vs -307.52% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "128.80",
          "val2": "89.50",
          "chgp": "43.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.30",
          "val2": "-60.10",
          "chgp": "61.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.80",
          "val2": "10.70",
          "chgp": "-8.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-99.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-48.60",
          "val2": "-184.20",
          "chgp": "73.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-360.10%",
          "val2": "-998.30%",
          "chgp": "63.82%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
128.80
89.50
43.91%
Operating Profit (PBDIT) excl Other Income
-23.30
-60.10
61.23%
Interest
9.80
10.70
-8.41%
Exceptional Items
0.00
-99.20
100.00%
Consolidate Net Profit
-48.60
-184.20
73.62%
Operating Profit Margin (Excl OI)
-360.10%
-998.30%
63.82%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 43.91% vs -36.07% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 73.62% vs -307.52% in Dec 2023

stock-summaryCompany CV
About Oxford Biomedica Plc stock-summary
stock-summary
Oxford Biomedica Plc
Pharmaceuticals & Biotechnology
Oxford BioMedica Plc is a gene and cell therapy company. The Company and its subsidiaries has developed lentiviral vector delivery platform (LentiVector), which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, liver and central nervous system (CNS) disorders. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401 and addresses neurodegenerative and a range of cancers. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
Company Coordinates stock-summary
Company Details
Windrush Court, Transport Way , OXFORD None : OX4 6LT
Registrar Details